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a  b  s  t  r  a  c  t
Premature  ventricular  contractions  (PVCs)  and  slow  coronary  ﬂow  phenomenon  (SCFP)  are  primarily
separate  entities.  Each  one  of  them  has different  characteristics  and a diverse  spectrum  of  presentation.
However,  and  despite  many  suggested  theories,  a comprehensive  understanding  of the  etiology  of  both
of them  is still  a matter  of debate.  PVCs,  which  can  be triggered  by consuming  cannabis  (marijuana),  and
through  decreasing  the  diastolic  time  (DT),  can  affect  the  slow  blood  ﬂow  found  in SCFP  even more  and
worsen  the  clinical  picture  in  patients  who  have  PVCs  and  SCFP.  In this  paper,  we present  a patient  who
uses  marijuana  and  has  PVCs  and SCFP,  try  to  address  different  aspects  of  PVCs  and  SCFP,  pinpoint  any
suspected  interaction  between  both  of  them  and  the  role  of marijuana  in this  context.
<Learning  objective:  (i)  PVCs  are  extra  abnormal  heartbeats  arising  in one  of  the  ventricles  and  dis-
rupting  the normal  rhythm  of the  heart.  (ii) PVCs  are very  common  and  occur  in  a  broad  spectrum  of  the
population  including  those  with  and  without  underlying  heart  disease.  (iii)  SCFP  is an  angiographic  ﬁnd-
ing  characterized  by  delayed  progression  of  the  contrast  injected  inside  large  coronary  arteries  without
any  signiﬁcant  CAD.  (iv) It has  an  incidence  of  1%  among  patients  who  undergo  coronary  angiography,
especially  those  presenting  with  acute  coronary  syndrome.  (v)  PVCs,  which  can  be  triggered  by consum-
ing  cannabis  (marijuana),  and throughout  decreasing  the  DT,  can  affect  the  slow  blood  ﬂow  found  in SCFP
even  more  and  worsen  the  clinical  picture  in patients  who  have  PVCs  and  SCFP.>
3  Jap©  201
ntroduction
Premature ventricular contractions (PVCs) are extra abnormal
eartbeats arising in one of the ventricles and disrupting the nor-
al  rhythm of the heart. PVCs are very common and occur in a
road spectrum of the population including those with and with-
ut underlying heart disease. They are more common in men
han women, in African Americans than whites, and in those with
rganic heart disease. The ability to detect recorded PVCs is mainly
epending on the period of monitoring, especially in asymptomatic
ndividuals.
Slow coronary ﬂow phenomenon (SCFP) is an angiographic ﬁnd-
ng characterized by delayed progression of the contrast injected
nside large coronary arteries without any signiﬁcant coronary
rtery disease (CAD). It was ﬁrst recognized in 1972. It is more com-
on  in male smokers [1], with an overall incidence of 1% among
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patients who  undergo coronary angiography, especially those pre-
senting with acute coronary syndrome [2].
Case report
A 37-year-old female with a history of mitral regurgitation
(MR), hypertension, and syncope, presented to the emergency
department with chest pain, dizziness, headache, and shortness
of breath for the past two  weeks. She also reported a history of
palpitations for many years, which have increased over the past
two weeks. Laboratory evaluation showed potassium of 3.6 mEq/L
(N = 3.5–5 mEq/L), magnesium of 1.9 mg/dL (N = 1.5–2.3 mg/dL),
and negative troponin times two. Urine was found to be positive
for opiates and marijuana. The patient admitted to using marijuana
for 10 years. Electrocardiography (ECG) at rest revealed normal
sinus rhythm with PVCs in a bigeminal pattern (Fig. 1). On exercise
stress test, the patient developed non-sustained run of ventricu-
lar tachycardia at almost 300 beats per minute. Chest X-ray and
computed tomography of the chest came back normal. Nuclear
medicine stress test was also normal with no evidence of reversible
ischemia or scar. Transthoracic echocardiogram showed abnormal
vier Ltd. All rights reserved.






































cFig. 1. Electrocardiogram of the patient showing normal sinus rhythm
eft ventricle diastolic ﬁlling pattern, PVCs, trace MR,  and an ejec-
ion fraction of 50–55%. To rule out any signiﬁcant CAD, cardiac
atheterization was done and revealed slow coronary blood ﬂow
ith a thrombolysis in myocardial infarction (TIMI) score of II in left
nterior descending (LAD) artery (Video 1) and mildly slow coro-
ary blood ﬂow with a TIMI score of II–III in right coronary artery
RCA) without any overt CAD. Occasional couplets without ectopy
nd mild MR  were also noted. The patient was put on the maximal
ose of metoprolol and counseled to abstain from marijuana with
 possibility to consider catheter ablation therapy in case she con-
inues to be symptomatic with documented PVCs and ventricular
achycardia after that.
Supplementary data associated with this article can be
ound, in the online version, at http://dx.doi.org/10.1016/j.jccase.
013.06.006.
iscussion
The prevelance of PVCs is increased in patients diagnosed with
ypertension (HTN) [3] especially when it is associated with left
entricular hypertrophy, dilated cardiomyopathy and heart failure
HF), post acute myocardial infarction (MI), and congenital heart
isease.
PVCs often cause no symptoms. In many patients, the pres-
nce of PVCs could result in the sensation of ﬂuttering, pounding,
kipped beats, palpitations, dizziness, and/or near syncope.
The etiology of PVCs is not well known. Many mechanisms may
xplain the origin of PVCs, including enhanced normal or abnormal
utomaticity inside the heart, triggered activity in Purkinje cells
f the ventricular myocardium, or reentry. Anxiety, alcohol, caf-
eine, tobacco, exercise, illicit drugs, hypokalemia, HTN, ischemia,
nfarction, excessive calcium, drug toxicity (such as digoxin), or an
nderlying heart disease could result in PVCs through previously
entioned mechanisms.
ECG is the mainstay of diagnosis of PVCs. This includes stan-
ard ECG, exercise stress ECG, holter monitor, and event recorder
epending primarily on the frequency of PVCs which helps to
ecide the best way to detect them.
Only in symptomatic patients do PVCs need to be diagnosed and
reated. Beside eliminating previously mentioned possible triggers,
eta blockers and calcium channel blockers are recommended as
rst-line therapy for symptomatic PVCs, especially with outﬂow
ract morphology in a structurally normal heart. Antiarrhythmic
edications, such as amiodarone can sometimes be tried but with
aution because of its side effects.iated with a bigeminal pattern of premature ventricular contractions.
Frequent PVCs may  be associated with worsening of systolic
heart failure in patients with a dilated cardiomyopathy. Small
studies have suggested that in selected patients, radiofrequency
ablation of ectopic ventricular foci is associated with an improve-
ment in left ventricular function and clinical improvement in
symptoms [4–7].
The 2006 American College of Cardiology/American Heart
Association/European Society of Cardiology guidelines for the
management of ventricular arrhythmias included suggestions
regarding ablation therapy for PVCs [8]. They note that ablation
therapy of PVCs may  be useful if they are frequent, symptomatic,
and monomorphic, if they are refractory to medical therapy, if the
patient chooses to avoid long-term medical therapy, or if they
consistently provoke ventricular arrhythmia storm of a similar
morphology [9].
SCFP, as a separate entity, has a widely diverse presentation
including chest discomfort, unstable angina, non ST elevation MI,
ST elevation MI  or nonsustained ventricular tachycardia. It usually
presents with recurrent rest pain requiring urgent admission.
The etiology of SCFP is not completely understood. It is spec-
ulated that it is caused by acute but recurrent perturbations of
microvascular function. Histopathological examination (light and
electron microscope) of left and right ventricular endomyocardial
biopsies taken from some patients showed ﬁbromuscular hyper-
plasia, myoﬁbrilar hypertrophy, endothelial degeneration with
swollen endothelial cells encroaching on the lumen, luminal size
reduction, mitochondrial abnormalities, lipofuscin deposition, and
glycogen content reduction, which can cause the elevation in
resting coronary artery resistances, especially toward microvas-
culature beds, found in SCFP. Normal and pathological zones
often coexisted in the same specimen (patchy appearance). Thus,
in some patients with slow coronary ﬂow and patent coro-
nary arteries, functional obstruction of microvessels seems to
be implicated, as it is relieved by dipyridamole infusion. This
shows also that small-vessel CAD can cause classic angina pec-
toris.
The diagnosis can be suspected when the coronary angiogram
shows large patent arteries with slow ﬂow of the angiographic con-
trast medium and it can be conﬁrmed by endomyocardial biopsy.
Another study suggested that elevation in plasma homocys-
teine, even if it is mild, may  play a role in the pathogenesis of SCFP by
severely disturbing vascular endothelial function and subsequently
impairing coronary blood ﬂow [10], and showed that patients
with SCFP have statistically signiﬁcant raised level of plasma
homocysteine compared to control subjects with normal coronary
ﬂow.
R.N. Khouzam et al. / Journal of Cardi
Fig. 2. Illustrating the changes in aortic pressure, blood ﬂow in left coronary artery
(LCA) and blood ﬂow in right coronary artery throughout normal cardiac cycle of





























and their effect on blood ﬂow in LCA (black shaded area) are shown for compari-
on.*, Isovolumetric contraction. #, Isovolumetric relaxation. (For interpretation of
eferences to color in this ﬁgure legend, the reader is referred to the web version of
his  article,)
As a treatment, dipyridamole, which has dilatator properties
n coronary microvessels, proved to be useful in most patients
ith SCFP. It abolishes functional obstruction in coronary arteries
ith diameters less than 200 m and is considered far superior
n treating SCFP as compared to nitroglycerine. Other therapies
roved to be effective also include simvastatin [11], atorvastatin
12], nebivolol [13], and mibefradil [14] although the use of the lat-
er is limited because of drug interactions caused by its inhibition
f the cytochrome P450 3A4 pathway [15].
Beside mean arterial pressure, blood ﬂow in coronary arteries
epends on heart contractility. During systole, and because of the
ig muscular mass of the left ventricle (LV), extravascular com-
ression prevents any antegrade blood ﬂow in left coronary artery
LCA) particularly at the end of isovolumetric contraction. Con-
ersely, and during diastole and especially early diastole which
epresents isovolumetric relaxation, coronary blood ﬂow in LCA
ecomes maximal (Fig. 2).
In right coronary artery (RCA), blood ﬂow is maximal during
eak systole, because extravascular compression within the right
entricle is less than its counterpart in the LV preserving antegrade
lood ﬂow in RCA in both systole and diastole.
The fact that the highest blood ﬂow in LCA occurs throughout
ifferent stages of diastole, which is not the case in RCA, assumes
hat any PVC happening through diastole will have a bigger impact
n blood ﬂow in LCA compared to RCA. This, in turn, will be reﬂected
s a slow blood ﬂow (low TIMI score) in LCA more than in RCA.In patients with SCFP, resting coronary artery resistances, as
entioned above, are abnormally elevated, however, these resis-
ances respond normally to vasodilator stimuli such as papaverine
nd adenosine and during exercise [16].ology Cases 8 (2013) 121–124 123
Marijuana affects the heart in different ways. The acute cardio-
vascular effects of marijuana, which are palpitations, tachycardia,
elevated blood pressure, and a greater myocardial oxygen demand,
are mainly caused by increased release of catecholamines. Chronic
use of marijuana can worsen any underlying disease through pro-
longed vasoconstriction and causes digital clubbing. Very high
doses of marijuana may  conversely cause bradycardia and hypoten-
sion [17].
After a thorough review of the literature, it was noted that there
was a lack of description of any speciﬁc timeframe, after which
marijuana consumption will have effects on the heart, resulting
in myocardial ischemia or heart failure. Patient’s age and the pres-
ence of underlying CAD are key players in determining how fast the
results of smoking marijuana will take effect on the heart, especially
when it comes to chronic use.
The mechanisms by which marijuana affects the heart are
diverse including increased cardiac work through elevated cat-
echolamines and carboxyhemoglobin levels, as well as possible
episodes of intense postural hypotension [18]. Moreover, smoking
cannabis was rarely found to trigger MI.  Among cannabis users who
sustained an acute MI,  the risk was nearly ﬁve times higher within
the ﬁrst hour after smoking compared to periods of nonuse (rela-
tive risk 4.8, 95% CI 2.9–9.5) [19]. The elevated risk rapidly declined
thereafter.
Increased release of catecholamines caused by marijuana can
enhance normal or abnormal automaticity inside the heart and sub-
sequently cause PVCs, which in turn, will reduce diastolic time (DT).
The reduction in DT in combination with the direct vasoconstric-
tive effect of marijuana, will potentially lead to “physiologic” slow
blood ﬂow in coronary arteries or exacerbate any baseline SCFP.
Conclusion
PVCs documented through ECG, SCFP reﬂected in low TIMI score
during coronary angiography, and marijuana use in symptomatic
patients, could or could not be etiologically related to each other,
but can exacerbate each other.
In this population of patients, breaking this vicious circle of
exacerbation must be given the priority. Counseling these patients
about abstaining from marijuana and starting them on a gradually
increasing dose of beta blockers to reach the maximal dose must
be at the top of the list of treatment options of PVCs and should be
tried before any further invasive procedures are considered.
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